Navigation Links
Human neural stem cells restore motor function in mice with chronic spinal cord injury
Date:8/19/2010

Irvine, Calif., Aug. 19, 2010 A UC Irvine study is the first to demonstrate that human neural stem cells can restore mobility in cases of chronic spinal cord injury, suggesting the prospect of treating a much broader population of patients.

Previous breakthrough stem cell studies have focused on the acute, or early, phase of spinal cord injury, a period of up to a few weeks after the initial trauma when drug treatments can lead to some functional recovery.

The UCI study, led by Aileen Anderson and Brian Cummings of the Sue & Bill Gross Stem Cell Research Center, is significant because the therapy can restore mobility during the later chronic phase, the period after spinal cord injury in which inflammation has stabilized and recovery has reached a plateau. There are no drug treatments to help restore function in such cases.

The study appears in the open-access, peer-reviewed journal PLoS ONE and is available online at http://dx.plos.org/10.1371/journal.pone.0012272.

The Anderson-Cummings team transplanted human neural stem cells into mice 30 days after a spinal cord injury caused hind-limb paralysis. The cells then differentiated into neural tissue cells, such as oligodendrocytes and early neurons, and migrated to spinal cord injury sites. Three months after initial treatment, the mice demonstrated significant and persistent recovery of walking ability in two separate tests of motor function when compared to control groups.

"Human neural stem cells are a novel therapeutic approach that holds much promise for spinal cord injury," said Anderson, associate professor of physical medicine & rehabilitation and anatomy & neurobiology at UCI. "This study builds on the extensive work we previously published in the acute phase of injury and offers additional hope to those who are paralyzed or have impaired motor function."

"About 1.3 million individuals in the U.S. are living with chronic spinal cord injury," added Cummings, associate professor of physical medicine & rehabilitation and anatomy & neurobiology. "This latest study provides additional evidence that human neural stem cells may be a viable treatment approach for them."

The research is the latest in a series of collaborative studies conducted since 2002 with StemCells Inc. that have focused on the use of StemCells' human neural stem cells in spinal cord injury and resulted in multiple co-authored publications. StemCells Inc., based in Palo Alto, Calif., is engaged in the research, development and commercialization of stem cell therapeutics and tools for use in stem cell-based research and drug discovery.

According to Dr. Stephen Huhn, vice president and head of the central nervous system program at StemCells Inc., "the strong preclinical data we have accumulated to date will enable our transition to a clinical trial, which we plan to initiate in 2011."


'/>"/>

Contact: Tom Vasich
tmvasich@uci.edu
949-824-6455
University of California - Irvine
Source:Eurekalert

Related medicine news :

1. Input-output trade-offs found in human information processing
2. Human Meds Are Pets Biggest Poisoning Danger
3. NIH launches effort to define markers of human immune responses
4. New human adenovirus may not make for good vaccines, after all
5. Human clinical trial of NIH-developed dengue vaccine begins
6. Human embryonic stem cells purified in new, rapid technique
7. Scientists develop the first model for investigating the origins of testicular cancer in humans
8. Scientists unravel human-ecosystem interactions
9. UCLA scientists for the first time identify a cell-of-origin for human prostate cancer
10. Plant compound resveratrol shown to suppresses inflammation, free radicals in humans
11. Non-human sugar in biotech drugs causes inflammation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... July 26, 2017 , ... Team Type 1 Foundation, a nonprofit ... everyone affected by diabetes, is excited to announce the 106 college athletes with type ... , Established in 2005, the Team Type 1 Foundation has bestowed a total of ...
(Date:7/26/2017)... Florida (PRWEB) , ... July 26, 2017 , ... ... for dogs and cats has opened in Jupiter. The state of the ... (cardiology) and class leading treatments with a goal of providing heart patients longer ...
(Date:7/26/2017)... ... 26, 2017 , ... Isodiol International Inc. (CSE: ISOL) (OTC: ... the development of pharmaceutical and consumer products, announces the operational numbers of its ... Iso International LLC recorded unaudited fiscal Q1 profits of $897,596 based on revenues ...
(Date:7/26/2017)... ... July 26, 2017 , ... Wendy M. Musielak, a partner at the Andrew Cores ... County Bar Association’s third Vice President earlier this year. She will serve the membership in ... second Vice President, in accordance with the organization’s by-laws. , Musielak joined the ...
(Date:7/26/2017)... ... July 26, 2017 , ... The number of adults ... United States, but ways to improve asthma control in the population are not well ... Practice (JACI: In Practice), an official journal of the American Academy of Allergy, Asthma ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... GAITHERSBURG, Md. , July 10, 2017 ... in non-animal test methods, is the recipient of a ... by the PETA International Science Consortium. The device, which ... be used to expose human lung cells to airborne ... lung. IIVS will use the VITROCELL® system for testing ...
(Date:7/6/2017)... the nutrition division of Diplomat Specialty Infusion Group, is celebrating a decade ... To celebrate its anniversary, ThriveRx recently launched a redesigned website at ... improved organization to create the best user experience for consumers and health ... Diplomat ... "We,ve made several great strides throughout the past ...
(Date:7/5/2017)... 5, 2017   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade cell and tissue ... ("BioLife"), today announced that it has reached an agreement ... largest shareholder, to modify its existing credit facility effective ... modification, WAVI agreed to exchange its existing $4.25 million ...
Breaking Medicine Technology: